EGFR and non-small cell lung carcinoma: At present, evaluation of the economics of osimertinib versus conventional EGFR-TKIs in first-line therapy with EGFR-mutated advanced NSCLC in the United States and Brazil achieved different ICERs per QALY, with $226,527 vs. erlotinib, $231,123 vs. gefitinib, and $219,874 vs. afatinib in the United States (Aguiar et al., 2018).